SciCombinator

Discover the most talked about and latest scientific content & concepts.

IN Sabir, GD Matthews and CL Huang
Abstract
Atrial fibrillation, the commonest cardiac arrhythmia, predisposes to thrombus formation and consequently increases risk of ischaemic stroke. Recent years have seen approval of a number of novel oral anticoagulants. Nevertheless, warfarin and aspirin remain the mainstays of therapy. It is widely appreciated that both these agents increase the likelihood of bleeding: there is a popular conception that this risk is greater with warfarin. In fact, well-managed warfarin therapy (INR 2-3) has little effect on bleeding risk and is twice as effective as aspirin at preventing stroke. Patients with atrial fibrillation and a further risk factor for stroke (CHA2DS2-VASc >0) should therefore either receive warfarin or a novel oral agent. The remainder who are at the very lowest risk of stroke are better not prescribed antithrombotic therapy. For stroke prevention in atrial fibrillation; aspirin is rarely the right choice.
Tweets*
11
Facebook likes*
1
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
1
Concepts
Heparin, Myocardial infarction, Thrombus, Anticoagulant, Thrombosis, Warfarin, Atrial fibrillation, Stroke
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com